| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6099309 | Journal of Crohn's and Colitis | 2014 | 9 Pages |
Abstract
The trough level 4.1 μg/mL may serve as cut-off for clinical remission. Drug trough levels decreased during treatment and almost all patients with undetectable s-infliximab and monotherapy had developed antibodies against the drug.
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Per Marits, Laura Landucci, Ulf Sundin, Loa Davidsdottir, Jakob Nilsson, Ragnar Befrits, Ann-Charlotte Wikström, Michael Eberhardson,